4,799 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Choreo LLC

Choreo LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 4,799 shares of the life sciences company’s stock, valued at approximately $503,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bouvel Investment Partners LLC lifted its position in shares of Illumina by 1.3% during the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after acquiring an additional 84 shares during the period. UMB Bank n.a. boosted its position in shares of Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after purchasing an additional 88 shares in the last quarter. STF Management LP grew its stake in shares of Illumina by 3.5% in the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after buying an additional 90 shares during the period. Gulf International Bank UK Ltd increased its position in Illumina by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock valued at $1,862,000 after buying an additional 98 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Illumina by 4.9% during the 1st quarter. GAMMA Investing LLC now owns 2,258 shares of the life sciences company’s stock worth $310,000 after buying an additional 105 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on ILMN. Robert W. Baird boosted their price objective on Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Citigroup boosted their price target on shares of Illumina from $140.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Piper Sandler dropped their price objective on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Evercore ISI dropped their price target on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 11th. Finally, Stephens reissued an “overweight” rating and set a $170.00 price objective on shares of Illumina in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $151.05.

Illumina Stock Performance

NASDAQ ILMN opened at $129.18 on Monday. The company’s 50 day simple moving average is $123.36 and its two-hundred day simple moving average is $120.69. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $152.87. The stock has a market capitalization of $20.58 billion, a PE ratio of -15.85 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the company posted $0.32 EPS. The company’s revenue for the quarter was down 5.4% on a year-over-year basis. Analysts predict that Illumina, Inc. will post 3.62 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.